Two de novo classifications were granted in March, bringing the 2016 total to three.
Bio-Rad Laboratories Inc.'s Amplicheck II assay controls and Sensimed AG's Sensimed Triggerfish intraocular pressure pattern detector were granted marketing access via the de novo pathway last month.